Resource id #3DrugId:1d00000127resource(4) of type (mysql result) Drug Search

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main   

Drug ID: 1d00000127

Drug Name: Asenapine

Generic Names: Asenapt (5mg) | Saphris

Category: Psychotherapeutics

Legal Status: Non Opioid Prescription only drug


Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Recommended Dose: The recommended starting and target dose is 5 mg given twice daily.

Recommended In: This medication is an atypical antipsychotic agent, prescribed for schizophrenia and acute mania with bipolar disorder. It changes the activity of certain natural substances in the brain.

Directions For Use: It comes as a tablet to be placed under the tongue, with or without food.

Storage: Store it at room temperature (25C).

Dosage Forms: Sub-lingual Tablet

Side Effects: Most Common - Brain disorder, movement disorder, weight increased and drowsiness.

Gastrointestinal - Constipation, dry mouth, motionless, increased saliva, stomach discomfort and vomiting.

General - Fatigue and irritability.

Metabolic - Increased appetite.

Central Nervous system - Weakness, dizziness and sleeplessness.

Heart - High blood pressure.

In Case of Overdose: Reported adverse reactions at the highest dosage included agitation and confusion. There is no specific antidote to Asenapine. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms.

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of Asenapine induced alpha blockade). In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.

Avoid If: Caution should be exercised in patients with history of high blood pressure, cancer, Alzheimer disease, dementia, Parkinson disease, or esophagus problems, low blood volume, alcoholism, heart, liver, and kidney diseases, any allergy, who are taking other medications, elderly, children, during pregnancy and breastfeeding.

It may cause drowsiness, dizziness, or lightheadedness, do not drive a car or operate machinery and get up slowly from bed while taking this medication.

Avoid alcohol consumption.

Avoid abrupt withdrawal; withdraw gradually.

Monitor complete blood cell counts, electrolyte levels, or fasting blood
sugar levels regularly while taking this medication.

Patient may develop with increased risk of neuroleptic malignant syndrome (NMS) with the following symptoms: fever; stiff muscles; confusion; abnormal thinking; fast or irregular heartbeat; and sweating. If it is so consult with your doctor.

Avoid contact with people who have infections.

Drink adequate fluid; otherwise it may lead to dehydration.

Avoid excess dosage.

It may affect blood sugar level; monitor sugar level regularly while taking this medication.

Contraindicated in patients with severe liver problems, heart diseases, who are taking antiarrhythmic, antipsychotic, phenothiazine, quinolone drugs and hypersensitivity.

Drug Interaction: The risks of using Asenapine in combination with other drugs have not been extensively evaluated. Given the primary CNS effects of Asenapine, caution should be used when it is taken in combination with other centrally acting drugs or alcohol.

Because of its ?1-adrenergic antagonism with potential for inducing hypotension, Asenapine may enhance the effects of certain antihypertensive agents.

Main    A    B    C    D    E    F    G    H    I    J    K    L    M    N    O    P    Q    R    S    T    U    V    W    X    Y    Z    Main